Stemcell Institute Inc. (7096)
JPX JPX Primary 
XKLS Summary
Stemcell Institute Inc. (7096) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Stemcell Institute Inc. ever had a stock split?
Stemcell Institute Inc. Profile
| Biotechnology Industry | Healthcare Sector | - CEO | JPX Exchange | JP3399640006 ISIN |
| Japan Country | 98 Employees | - Last Dividend | 29 Dec 2022 Last Split | - IPO Date |
Overview
StemCell Institute Inc. is a prominent player in the stem cell industry based in Tokyo, Japan. Since its establishment in 1999, the company has focused on stem cell banking, positioning itself as a crucial resource in the field of regenerative medicine. It operates as a subsidiary of Trim Medical Holdings Inc., which underscores its significant role within a larger network of medical research and healthcare services. StemCell Institute Inc. extends its expertise to the development and research of innovative medical treatments that leverage the potential of stem cells. This endeavor aligns with the global pursuit of groundbreaking therapies for various diseases, highlighting the company's commitment to advancing medical science and healthcare solutions.
Products and Services
- Stem Cell Banking:
- Research and Development in Medical Treatments using Stem Cells:
- Banking of Blood Vessel Cells:
This service provides clients the opportunity to bank their stem cells for future medical use. StemCell Institute Inc. uses cutting-edge technologies to preserve these cells, ensuring their viability for potential therapeutic applications. This foresight offers peace of mind to clients, knowing their cells can be utilized in emerging treatments for various conditions.
At the forefront of innovation, StemCell Institute Inc. is deeply involved in the research and development of medical treatments that utilize stem cells. This area of their work is vital for discovering new therapeutic approaches that can treat or potentially cure a wide range of diseases. The company's research efforts contribute significantly to the advancement of regenerative medicine, aiming to improve patient outcomes and quality of life.
Expanding its banking services beyond stem cells, the company also specializes in the preservation of blood vessel cells. This unique service caters to future medical procedures that might require the use of a patient's own vascular cells for treatments or surgeries. Banking blood vessel cells is an innovative approach that could play a crucial role in vascular therapies and regenerative treatments.
